Released Nov 9, 2020, before the open
10-Q filed Nov 9, 2020, 40 days after period end · 0001564590-20-052190
Q3 2020 · 10-Q
Revenue—
Net Income-$9.15M-$9.15M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.18-$0.18 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$8,961,000N/M
Operating Cash Flowderived-$7,169,000N/M
Free Cash Flowderived-$7,176,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2020 | Q3 2019 |
|---|---|---|
| Net Income | -$9.15M | -$8.55M |
| EPS Diluted | -$0.18 | -$1.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR